# First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.

> **NCT07377253** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Giuseppe Pantaleo** · enrollment: 18 (estimated)

## Conditions studied

- The Tick-borne Encephalitis Virus (TBEV)

## Interventions

- **DRUG:** Human monoclonal antibody TBE025, intravenous infusion

## Key facts

- **NCT ID:** NCT07377253
- **Lead sponsor:** Giuseppe Pantaleo
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07377253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07377253, "First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07377253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*